Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in…
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer…
Event to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease…
The Acquisition is Expected to Create Immediate Synergies with the Company’s Existing Medical Device Business BEIJING, March 25, 2025 (GLOBE…
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with…
Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID…
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel,…
WARRINGTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company…
On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL…
First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian…